Muna Naash, Ph.D. - OU Medicine

Duration: 2007-2012
Title: Mechanism of photoreceptor cell degeneration in animal model of human retinal
diseases
Agency: NIH/National Eye Institute R01 (EY010609) PI: Naash
Duration: 2005-2009
Title: Evaluation the efficacy of Acucela drug on ABCR null mice.
Agency: Acucela Inc. PI: Naash
Duration: 2006-2008
Title: Sustained, Non-viral Ocular Therapy Using Nanoparticles
Agency: NIH/National Eye Institute R03 (EY016201) PI: Naash
Duration: 2005-2008
Title: Stem cell therapy in animal models of retinal degeneration PI: Naash
Agency: Johnson & Johnson Pharmaceutical
Duration: 2005-2008
Title: Oklahoma IDeA Network of Biomedical Research Excellence PI: Waxman
Agency: NIH-INBRE, P20 RR016478
Duration: 2004-2009
Role: Mentor
Title: Core Grant for Vision Research PI: Anderson
Agency: NIH/NEI - P30 EY12190-09
Duration: 2004-2009
Role: Member
PAST/COMPLETED
Oklahoma Center for the Advancement of Science and Technology (OCAST), PI: Naash (Gene Therapy
for Ocular Diseases Using Nanotechnology), 2004-2007.
Foundation Fighting Blindness, Inc., PI: Naash, (Delivery and targeting of ocular therapeutics using
nanotechnology), 2004-2007.
Macular Society, PI: Naash, (Non-viral gene therapy to rescue a mouse model of macular dystrophy),
2005-2006.
NIH/NEI, R01 (EY10609), PI: Naash (supplement for transgenic mice rederivation), 2004-2006
INSPIRE Pharmaceuticals, Inc., PI: Naash, (Microarray studies to isolate modulating genes by the P2Y2
Receptor Agonists in Mouse Model of retinal detachment).
NIH/NEI (Mentoring Vision Research in Oklahoma), Mentor, 2002-2007.
NIH/NEI, R01 (EY10609), PI: Naash (Mechanisms of photoreceptor cell degeneration in animal models
for human retinal diseases),1999-2005, $1,830,440.
Oklahoma Center for the Advancement of Science and Technology (OCAST), PI: Naash (Ribozyme
Therapy for Stationary Night Blindness), 2001-2004.
INSPIRE Pharmaceuticals, Inc., PI: Naash, (Therapeutic Application of P2Y2 Receptor Agonists in
Transgenic Mouse Models of Retinal Degeneration).
The Foundation Fighting Blindness, PI: Naash, (Efficiency and specificity of ribozyme therapy), 2000-
2003.
Research to Prevent Blindness, PI: Naash, (Rescue of visual loss in animal models for retinal diseases),
2000.
The Foundation Fighting Blindness, PI: Naash, (Ribozyme therapy for rhodopsin mutations that cause
autosomal dominant retinitis pigmentosa) 1999-2002.
March of Dime, Co-PI: Naash, (Generation of transgenic mice expressing P23H mutation in the human
opsin gene), 1999-2000.
The Foundation Fighting Blindness, PI: Naash, (UIC Center Grant- Studies on the mechanism of
photoreceptor cell death), 1997-2000.
Macular Society, PI: Naash, (Animal model for juvenile macular degeneration due to a mutation in
peripherin/rds gene), 1998-1999.
The Foundation Fighting Blindness, PI: Naash, (Ribozyme therapy for autosomal dominant retinitis
pigmentosa), 1996-1999.
CURRICULUM VITA FOR MUNA I. NAASH, PHD 2